BRPI0608334A2 - use of a powdered clobetasol formulation for the treatment of psoriasis - Google Patents

use of a powdered clobetasol formulation for the treatment of psoriasis

Info

Publication number
BRPI0608334A2
BRPI0608334A2 BRPI0608334-0A BRPI0608334A BRPI0608334A2 BR PI0608334 A2 BRPI0608334 A2 BR PI0608334A2 BR PI0608334 A BRPI0608334 A BR PI0608334A BR PI0608334 A2 BRPI0608334 A2 BR PI0608334A2
Authority
BR
Brazil
Prior art keywords
psoriasis
treatment
clobetasol
powdered
formulation
Prior art date
Application number
BRPI0608334-0A
Other languages
Portuguese (pt)
Inventor
Gordon J Dow
Daniel M Stewart
Original Assignee
Dow Pharmaceutical Sciences
Dermatologix Partners Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences, Dermatologix Partners Inc filed Critical Dow Pharmaceutical Sciences
Publication of BRPI0608334A2 publication Critical patent/BRPI0608334A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Abstract

USO DE UMA FORMULAçãO DE CLOBETASOL EM LìQUIDO PULVERIZADO PARA O TRATAMENTO DE PSORIASE. A presente invenção provê um uso de uma composição farmacêutica contendo uma quantidade efetiva de propionato de clobetasol, uma composição farmacêutica preferida contendo propionato de clobetasol, álcool etílico, miristato de isopropila e agente tensoativo aniónico para a preparação de um medicamento, pulverizado sobre a pele afligida com psoriase diariamente por pelo menos quatro semanas, para o tratamento de psoriase.USE OF A CLOBETASOL FORMULATION IN SPRAY FOR PSORIASE TREATMENT. The present invention provides a use of a pharmaceutical composition containing an effective amount of clobetasol propionate, a preferred pharmaceutical composition containing clobetasol propionate, ethyl alcohol, isopropyl myristate and anionic surfactant for the preparation of a medicament sprayed onto the afflicted skin. with psoriasis daily for at least four weeks for psoriasis treatment.

BRPI0608334-0A 2005-04-25 2006-04-20 use of a powdered clobetasol formulation for the treatment of psoriasis BRPI0608334A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67494605P 2005-04-25 2005-04-25
PCT/US2006/014903 WO2006115987A2 (en) 2005-04-25 2006-04-20 Use of a clobetasol spray formulation to treat psoriasis

Publications (1)

Publication Number Publication Date
BRPI0608334A2 true BRPI0608334A2 (en) 2009-12-01

Family

ID=37215257

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608334-0A BRPI0608334A2 (en) 2005-04-25 2006-04-20 use of a powdered clobetasol formulation for the treatment of psoriasis

Country Status (18)

Country Link
US (2) US20060239929A1 (en)
EP (1) EP1885373B1 (en)
JP (1) JP2008539236A (en)
KR (2) KR20110108426A (en)
CN (1) CN101208096A (en)
AU (1) AU2006241285B2 (en)
BR (1) BRPI0608334A2 (en)
CA (1) CA2607434A1 (en)
DK (1) DK1885373T3 (en)
ES (1) ES2539634T3 (en)
HU (1) HUE025462T2 (en)
MX (1) MX2007013230A (en)
PL (1) PL1885373T3 (en)
PT (1) PT1885373E (en)
RU (1) RU2397769C2 (en)
SI (1) SI1885373T1 (en)
WO (1) WO2006115987A2 (en)
ZA (1) ZA200709327B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120142605A1 (en) * 2009-05-05 2012-06-07 Amgen Inc. Methods of treating psoriasis
EP3141246A1 (en) * 2009-08-31 2017-03-15 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US8992994B2 (en) 2010-10-21 2015-03-31 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
US9789123B2 (en) 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
KR101930244B1 (en) 2014-03-11 2018-12-18 프로미우스 파마 엘엘씨 Topical corticosteroid compositions
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
WO2017037663A1 (en) 2015-09-02 2017-03-09 Cadila Healthcare Limited Topical compositions comprising corticosteroids
KR102399484B1 (en) 2015-09-15 2022-05-17 주식회사 엘지생활건강 Soluble microneedle patch for delivery of antipsoriatic drug
KR102631435B1 (en) 2016-06-10 2024-01-29 주식회사 엘지생활건강 Soluble microneedle patch for delivery of drug for contusion
US20210069214A1 (en) * 2019-09-06 2021-03-11 Encore Dermatology, Inc. Topical compositions comprising a corticosteroid for the treatment of psoriasis in pediatric patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US5886038A (en) * 1998-03-24 1999-03-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US5990100A (en) * 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US6579512B2 (en) * 2001-06-15 2003-06-17 Crutchfield, Iii Charles E. Topical steroid spray

Also Published As

Publication number Publication date
WO2006115987A8 (en) 2008-10-16
RU2397769C2 (en) 2010-08-27
US20060239929A1 (en) 2006-10-26
PT1885373E (en) 2015-09-10
AU2006241285B2 (en) 2011-04-14
MX2007013230A (en) 2008-04-17
SI1885373T1 (en) 2016-03-31
KR20080047312A (en) 2008-05-28
JP2008539236A (en) 2008-11-13
WO2006115987A3 (en) 2006-12-14
HUE025462T2 (en) 2016-02-29
WO2006115987A2 (en) 2006-11-02
ZA200709327B (en) 2009-01-28
CN101208096A (en) 2008-06-25
US20140148426A1 (en) 2014-05-29
EP1885373A2 (en) 2008-02-13
AU2006241285A1 (en) 2006-11-02
PL1885373T3 (en) 2015-12-31
KR20110108426A (en) 2011-10-05
DK1885373T3 (en) 2015-08-10
ES2539634T3 (en) 2015-07-02
EP1885373B1 (en) 2015-05-20
CA2607434A1 (en) 2006-11-02
RU2007143420A (en) 2009-06-10
EP1885373A4 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
BRPI0608334A2 (en) use of a powdered clobetasol formulation for the treatment of psoriasis
CY1118059T1 (en) ANTIBODY COMPOSITIONS BASED ON FAT FOR TREATMENT OF PULMONARY INFECTIONS
BR0214794A (en) absorbent article wearer system for improving skin health
BR0314763A (en) Treatment of fungal infections
DE60232178D1 (en) DEVICE FOR TOPICAL ADMINISTRATION
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
AR059350A1 (en) PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST A TENSIOACTIVE SUBSTANCE
GT199900203A (en) CELECOXIB COMPOSITIONS.
CL2008002720A1 (en) Transdermic pharmaceutical composition for nebulizing, without alcohol, comprising one or more drugs, the enhancers of transdermal penetration diethylene glycol ethers or ester sunscreens, and non-volatile liquids; measured nebulization dosing device comprising it; manufacturing method; And its use.
UA93496C2 (en) Immune response modifier compositions and method for the preparation thereof
GT199900197A (en) ANTIPARASITARY FORMULATIONS.
UY30762A1 (en) SMOKE SALT OF (ALFA S, BETA R) -6-BROMO-ALFA- [2 (DIMETILAMINO) ETIL] -2-METOXI-ALFA-1-NAFTALENIL-BETA-PHENYL-3-QUINOLINAETHANOL
BRPI0511209A (en) pharmaceutical composition and use of a combination of clobetasol propionate and calcitriol
BRPI0415953A (en) oral controlled release dosage formulation, method of treating a disorder, set of controlled release dosage forms and method for administering the formulation
BRPI0518554A2 (en) use of a pde3 inhibitor
BR0113148A (en) 2-Pyridinamine Compositions and Related Methods
BR0311903A (en) Treatment for depression and anxiety by combining an iv pde inhibitor and an antidepressant or anxiolytic agent
BRPI0411702B8 (en) use of hyaluronic acid to prepare compositions for the treatment of thrush of the oral cavity
ECSP066649A (en) EFFECTIVE PREPARATION OF A PHARMACEUTICALLY ACTIVE BASIC SUBSTANCE
BRPI0618370A2 (en) aerosol drug formulation, drug use and inhalation kit
AR036321A1 (en) METHOD AND PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF LATE APPEARANCE DYSCINESIA.
CL2004001010A1 (en) COMPOUNDS DERIVED FROM MACROLIDS OF 14 OR 15 MEMBERS, REPLACED IN POSITION 4 "; PROCEDURE FOR PREPARATION; PHARMACEUTICAL COMPOSITION THAT INCLUDES IT; AND ITS USE FOR THE TREATMENT OR PROFILAXIS OF SYSTEMIC MICROBIAL OR TOPICAL INFECTIONS
BR112023001283A2 (en) TOPICAL PHARMACEUTICAL COMPOSITION; METHOD FOR TREATMENT OF AN INFLAMMATORY SKIN DISEASE, DISORDER, OR AFFECTION IN AN INDIVIDUAL IN NEED OF THE SAME; AND METHOD FOR ENHANCED SKIN PENETRATION IN A SUBJECT OF A TOPICAL PHARMACEUTICAL FORMULATION
DE602006005637D1 (en) ENTPIGMENTIZING BZW. CREAMING COSMETICS COMPOSITION CONTAINING AT LEAST ONE OXAZOLINE AS AN ACTIVE SUBSTANCE
BRPI0504082A (en) medicinal refreshing emulsions

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL